Lenadogene nolparvovec

N/A

Report date: 2023/10/26 16:03:18

Base Information

Drug NameLenadogene nolparvovec

Drug Alias NameND4基因治疗RAAV2/2-ND4 vectorrAAV2/2-ND4Recombinant AAV vector serotype 2 containing the human wild type mitochondrial ND4 geneLumevoq +[6]

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2 vector

Mechanisms of ActionMT-ND4 gene transference

TargetsNADH-ubiquinone oxidoreductase chain 4

Therapy Area/IndicationsOptic Atrophy, Hereditary, Leber

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumUnited StatesTaiwan +[9]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesGensight Biologics

China Registration ClassN/A

Develop Information

Active CompaniesGensight Biologics

Inactive CompaniesN/A

Active IndicationsOptic Atrophy, Hereditary, Leber

Inactive IndicationsN/A

Other Information

ATC CodeN/A